Checkmate Pharmaceuticals Inc., of Cambridge, Mass., said it completed a $22 million financing led by a new investor, Decheng Capital. The proceeds will support ongoing clinical development of its lead product, CMP-001, in advanced melanoma and non-small-cell lung cancer refractory to prior anti-PD-1 therapy, along with expansion into additional solid tumor types.